-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4471 Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Program: Oral and Poster Abstracts
Session: 626. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
Hematology Disease Topics & Pathways:
Lymphomas, Non-Hodgkin lymphoma, B Cell lymphoma, Diseases, Aggressive lymphoma, Treatment Considerations, Lymphoid Malignancies
Monday, December 9, 2024, 6:00 PM-8:00 PM

Leyre Bento1*, Fernando Martín Moro2*, Antonio Gutierrez, MD, PhD1*, Ana Jiménez Ubieto3*, Alberto López4*, Blanca Sánchez González5*, Belén Navarro6*, Alicia Segura6*, Mireia Franch7*, Ana García-Noblejas8*, Eva Donato9*, Alejandro Martín García-Sancho10*, Beatriz De La Cruz11*, Alfonso Ortiz Algarra12*, Roberto Trelles-Martínez13*, Javier López14*, Carlos Grande15* and Mariana Bastos-Oreiro16*

1Hematology Department, Son Espases University Hospital, IdISBa, Palma, Spain
2Hematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
3Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
4Hematology Department, Fundación Jiménez Díaz, Madrid, Spain
5Hematology Department, Hospital del Mar, Barcelona, Spain
6Hematology Department, Hospital Universitario Puerta de Hierro, Majadahonda, Spain
7Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Barcelona, Spain
8Hematology Department, Hospital La Princesa, Madrid, Spain
9Hematology Department, Hospital Universitario Doctor Peset, Valencia, Spain
10Hematology Department, Salamanca University Hospital, IBSAL, CIBERONC, Salamanca, Spain
11Hematology Department, Hospital Universitario La Paz, Madrid, Spain
12Hematology Department, Hospital Clínico de Valencia, Valencia, Spain
13Hematology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain
14Hematology, Hospital Universitario Ramón y Cajal, Madrid, Spain
15Hematology Department, Clínica Universidad de Navarra, Madrid, Spain
16Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Introduction

Large B cell lymphoma (LBCL) presents as limited stage (LS) in 25-30% of patients. This subgroup has been defined as I-II Ann Arbor (AA) stage with non-bulky disease (commonly <10 cm). Prognosis is favorable with overall survival (OS) at 10 years at least of 70-80%. The IPI has limited utility as most patients by definition have a favorable risk profile, so the stage modified IPI (smIPI) was developed including age >60 years, II AA stage, elevated LDH and ECOG >1 as poor-risk features. Improvements in the knowledge of disease biology, the availability of positron-emission tomography (PET) and clinical trials including only this population have changed the treatment paradigm. However, there has been still a heterogeneity in the optimal approach. The aim of this study is to analyze the real-world epidemiology of these patients including biological markers, extranodal sites and different treatment strategies for patients with LS-LBCL in Spain.

Patients and methods

We performed a retrospective multicenter study including patients from GELTAMO centers with LS-LBCL from January 2013 to December 2022. Diffuse LBCL NOS, high-grade B-cell lymphoma (HGBCL) double hit and NOS, transformed follicular lymphoma and other less frequent LBCL subtypes were included. Primary mediastinal, central nervous system, cutaneous lymphoma and patients with bulky mass >10cm were excluded. Disease status was assessed by PET/CT. The primary endpoints were response rate, progression-free survival (PFS) and overall survival (OS) in the overall series and depending on the different treatment strategies such as combined modality treatment using abbreviated R-CHOP (x 3-4 cycles) plus involved-site radiation therapy (RT), abbreviated R-CHOP alone with 4 cycles and standard R-CHOP consisting of 6 cycles.

Results

Four-hundred and thirty-five patients fulfilled the inclusion criteria; median follow-up 62 months (95%CI 56-69); median age 68 years (range 22-96); 91% diffuse LBCL NOS subtype, 5% HGBCL (4% double hit and 1% NOS); 75%, 85% and 46% had BCL2, BCL6 and MYC expression, respectively; 43% were non-germinal centre by Hans algorithms; 48% II AA stage; 31% with high LDH; 56% with extranodal disease (34% gastrointestinal, 15% head/neck and 51% other different sites) and 48% with smIPI ≥2. Regarding therapeutic approaches, 12% received R-CHOP x 3-4 plus RT, 19% R-CHOP x 4, 41% R-CHOP x 6, 20% other chemoimmunotherapy strategies and 7% palliative treatment. Overall and complete response rate at end of induction were 390 (93%) and 375 (89%), respectively.

Focusing on the cohort of patients that exclusively received R-CHOP x 3-4 plus RT, R-CHOP x 4 and R-CHOP x 6 (318/435, 73%), PFS and OS at 5 years were 80% (95%CI 68-83) and 88% (95%CI 81-90), respectively. The frequency of these strategies was maintained in different time periods. These 3 subgroups were comparable depending on biological and clinical characteristics except for BCL2 rearrangement, II AA stage, high LDH, extranodal disease and smIPI >1 which were more frequent in R-CHOP x 6 subgroup. These variables were included as potential confounders in the multivariate analysis for PFS and OS. PFS was influenced by age, ECOG, BCL6 expression, BCL2 and MYC rearrangement and smIPI (p<0.001). In the multivariate analysis, ECOG >1 [HR 2.6 (95%IC 1.1-6.3), p=0.031] was the only independent variable for PFS. OS was influenced by age, ECOG, BCL2 and MYC rearrangement and smIPI (p<0.001). In the multivariate analysis, age >60 years [HR 3.1 (95%IC 1.5-6.4), p=0.002] and ECOG>1 [HR 4.4 (95%IC 2.1-9.2), p<0.001] were the only variables associated with worse OS.

Conclusions

To our knowledge, this is the largest series analyzing patients with LS-LBCL in which 56% of patients had extranodal sites and 5% were diagnosed with HGBCL. Our real-world results do not suggest differences between R-CHOP x 3-4 plus RT, R-CHOP x 4 and R-CHOP x 6 strategies in terms of both PFS and OS as had already been shown in clinical trials. However, in our series R-CHOP x 6 was the most used strategy. It is planned to analyze the impact of PET on the therapy decision in this cohort.

Disclosures: Bento: Lilly: Consultancy; Kite/Gilead: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Roche: Honoraria, Speakers Bureau; Abbvie: Consultancy; Takeda: Honoraria, Speakers Bureau; Novartis: Honoraria, Speakers Bureau; Incyte: Honoraria, Speakers Bureau. Jiménez Ubieto: Lilly: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Speakers Bureau; Novartis: Speakers Bureau; AstraZeneca: Membership on an entity's Board of Directors or advisory committees; Roche: Consultancy, Speakers Bureau; Regeneron Pharmaceuticals, Inc.: Consultancy; Sandoz: Speakers Bureau; Incyte: Speakers Bureau; Kite-Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genmab: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Martín García-Sancho: IDEOGEN: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Other: Travel and Accommodation Support; BeiGene: Consultancy, Honoraria; Gilead/Kite: Consultancy, Honoraria, Other: Travel and Accommodation Support; EUSA Pharma: Honoraria; Kyowa Kirin: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: Travel and Accommodation Support; Roche: Honoraria, Other: Travel and Accommodation Support; Sobi: Consultancy, Honoraria; Takeda: Honoraria; AbbVie: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria; Genmab: Consultancy, Honoraria; GSK: Consultancy, Honoraria; Lilly: Consultancy, Honoraria; Miltenyi Biotec: Consultancy, Honoraria; Novartis: Consultancy. Bastos-Oreiro: Janssen: Honoraria; Kite: Honoraria, Research Funding; Incyte: Honoraria; Lilly: Honoraria; Genmab: Honoraria; Sobi: Honoraria; Astrazeneca: Honoraria; Abbvie: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Takeda: Honoraria; BMS: Honoraria; Roche: Honoraria, Research Funding.

*signifies non-member of ASH